BR112018001387A2 - composição de absorção percutânea, e, agente para promover a absorbabilidade transdérmica de um medicamento básico - Google Patents

composição de absorção percutânea, e, agente para promover a absorbabilidade transdérmica de um medicamento básico

Info

Publication number
BR112018001387A2
BR112018001387A2 BR112018001387-0A BR112018001387A BR112018001387A2 BR 112018001387 A2 BR112018001387 A2 BR 112018001387A2 BR 112018001387 A BR112018001387 A BR 112018001387A BR 112018001387 A2 BR112018001387 A2 BR 112018001387A2
Authority
BR
Brazil
Prior art keywords
basic
promote
absorption composition
agent
percutaneous absorption
Prior art date
Application number
BR112018001387-0A
Other languages
English (en)
Japanese (ja)
Other versions
BR112018001387B8 (pt
BR112018001387B1 (pt
Inventor
Miwa Yasushi
Hamamoto Hidetoshi
Akazama Naoya
Original Assignee
Medrx Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medrx Co., Ltd. filed Critical Medrx Co., Ltd.
Publication of BR112018001387A2 publication Critical patent/BR112018001387A2/pt
Publication of BR112018001387B1 publication Critical patent/BR112018001387B1/pt
Publication of BR112018001387B8 publication Critical patent/BR112018001387B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

o objetivo da presente invenção é fornecer: uma composição de absorção transdérmica tendo propriedades melhoradas de penetração do fármaco básico na pele; e um acelerador de absorção transdérmica para um fármaco básico. o objetivo pode ser alcançado por uma composição de absorção transdérmica compreendendo um fármaco básico ou um sal do mesmo e ácido sórbico e/ou um sal metálico de ácido sórbico. é preferido que o teor do componente de ácido sórbico seja de 0,5 a 2,5 mols com relação a 1 mol do fármaco básico. também é preferido que a composição de acordo com a presente invenção contenha adicionalmente um composto básico orgânico e/ou um componente básico inorgânico.
BR112018001387A 2015-08-29 2016-08-29 Composição de absorção percutânea, e, emplastro tipo matriz BR112018001387B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPPCT/JP2015/074553 2015-08-29
PCT/JP2015/074553 WO2017037813A1 (ja) 2015-08-29 2015-08-29 塩基性薬物とソルビン酸とを含有する経皮吸収組成物
PCT/JP2016/075203 WO2017038767A1 (ja) 2015-08-29 2016-08-29 経皮吸収組成物

Publications (3)

Publication Number Publication Date
BR112018001387A2 true BR112018001387A2 (pt) 2018-09-11
BR112018001387B1 BR112018001387B1 (pt) 2023-09-05
BR112018001387B8 BR112018001387B8 (pt) 2024-03-05

Family

ID=58187853

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001387A BR112018001387B8 (pt) 2015-08-29 2016-08-29 Composição de absorção percutânea, e, emplastro tipo matriz

Country Status (15)

Country Link
EP (1) EP3342423B1 (pt)
JP (2) JP6259117B2 (pt)
KR (1) KR20180039622A (pt)
CN (1) CN107427509B (pt)
BR (1) BR112018001387B8 (pt)
CO (1) CO2018001831A2 (pt)
ES (1) ES2864017T3 (pt)
MX (1) MX2018002015A (pt)
MY (1) MY189987A (pt)
PH (1) PH12018500271A1 (pt)
RU (1) RU2702356C2 (pt)
SG (1) SG11201800043UA (pt)
UA (1) UA123212C2 (pt)
WO (2) WO2017037813A1 (pt)
ZA (1) ZA201800296B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559519B2 (en) 2018-01-31 2023-01-24 Medrx, Co., Ltd. Tizanidine therapy system
WO2023062201A1 (en) * 2021-10-15 2023-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of tizanidine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61172830A (ja) * 1985-01-26 1986-08-04 Showa Denko Kk 皮膚外用剤組成物
JP4703075B2 (ja) * 1999-07-27 2011-06-15 久光製薬株式会社 外用貼付剤
US20040142024A1 (en) * 1999-07-27 2004-07-22 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use
WO2005089728A2 (en) * 2004-03-19 2005-09-29 Pfizer Health Ab Means for transdermal administration of nicotine
JP4807974B2 (ja) * 2005-06-30 2011-11-02 帝國製薬株式会社 経皮吸収促進組成物
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101143127A (zh) * 2007-10-25 2008-03-19 复旦大学 一种酚妥拉明外用制剂及其制备方法
AU2008327436B2 (en) * 2007-11-22 2013-09-05 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
ES2778724T3 (es) * 2008-02-27 2020-08-11 Hisamitsu Pharmaceutical Co Parche
JP2012158521A (ja) * 2009-04-17 2012-08-23 Kureha Corp 外用剤
US9168232B2 (en) * 2009-09-07 2015-10-27 Nipro Patch Co., Ltd. Transdermally absorbable preparation
AU2011267348A1 (en) * 2010-06-18 2012-10-25 Merz Pharma Gmbh & Co. Kgaa Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives
WO2013191187A1 (ja) * 2012-06-20 2013-12-27 株式会社メドレックス 薬剤と有機溶媒と親油性膏体基剤と粉体を配合した貼付製剤組成物

Also Published As

Publication number Publication date
CN107427509B (zh) 2021-06-15
EP3342423A4 (en) 2018-07-25
BR112018001387B8 (pt) 2024-03-05
JP6259117B2 (ja) 2018-01-10
ZA201800296B (en) 2019-04-24
ES2864017T3 (es) 2021-10-13
WO2017037813A1 (ja) 2017-03-09
MX2018002015A (es) 2018-06-19
CO2018001831A2 (es) 2018-05-21
PH12018500271A1 (en) 2018-08-13
JPWO2017038767A1 (ja) 2017-09-07
UA123212C2 (uk) 2021-03-03
EP3342423B1 (en) 2021-03-10
SG11201800043UA (en) 2018-02-27
MY189987A (en) 2022-03-22
RU2018110617A (ru) 2019-09-30
RU2702356C2 (ru) 2019-10-08
EP3342423A1 (en) 2018-07-04
JP2017149782A (ja) 2017-08-31
RU2018110617A3 (pt) 2019-09-30
BR112018001387B1 (pt) 2023-09-05
WO2017038767A1 (ja) 2017-03-09
KR20180039622A (ko) 2018-04-18
CN107427509A (zh) 2017-12-01

Similar Documents

Publication Publication Date Title
BR112015029144A2 (pt) formulações de gel para guiar radioterapia
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112017009252A2 (pt) solução de nicotina, sistema eletrônico de fornecimento de vapor, processo para melhorar as propriedades sensoriais de uma solução de nicotina vaporizada e uso de um ou mais ácidos
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112016013299A2 (pt) Composto
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112016021648A2 (pt) novos compostos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112018003232A2 (pt) terapias de combinação para tratamento de câncer
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112013020456A2 (pt) nova composição antifúngica
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112013028786A2 (pt) método e composição de tratamento de sementes
CO2017005201A2 (es) Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona
BR112018002520A2 (pt) Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
BR112015026631A2 (pt) compostos ou sais farmaceuticamente aceitáveis dos mesmos e respectivos usos, composição farmacêutica e método para prevenir ou tratar diabetes melito em mamífero
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/08/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2748 DE 05/09/2023, QUANTO AO ITEM (72) NOME DO INVENTOR.